Incyte:Expects to File Supplemental Biologics License Application for Tafasitamab in Combination With Lenalidomide and Rituximab in Fl by End of Year
因塞特:預計年底前申請生物製品執照補充申請,用於結合來那度胺和利妥昔單抗治療FL。
Incyte:Expects to File Supplemental Biologics License Application for Tafasitamab in Combination With Lenalidomide and Rituximab in Fl by End of Year
因塞特:預計年底前申請生物製品執照補充申請,用於結合來那度胺和利妥昔單抗治療FL。
使用瀏覽器的分享功能,分享給你的好友吧